|
| Tuesday, January 9, 2018 |
|
|
Eisai and Merck & Co. Receive Breakthrough Therapy Designation from U.S. FDA for LENVIMA and KEYTRUDA |
| The LENVIMA and KEYTRUDA combination therapy is being jointly developed by Eisai and MSD. This is the second Breakthrough Therapy Designation for LENVIMA and the twelfth Breakthrough Therapy Designation granted to KEYTRUDA. more info >> |
|
| Wednesday, December 27, 2017 |
|
|
Eisai: Anticancer Agent Lenvatinib Designated for Priority Review and Approval by CFDA for Hepatocellular Carcinoma |
| Eisai Co., Ltd. announced that its in-house discovered and developed anticancer agent lenvatinib mesylate for use in the treatment of HCC, which was submitted for approval in China in October 2017, has been designated for Priority Review and Approval by CFDA due to lenvatinib's significant clinical benefit compared to existing treatments. more info >> |
|
| Friday, December 22, 2017 |
|
|
Eisai: Adaptive Phase II Study of BAN2401 In Early Alzheimer's Disease Continues Toward 18-Month Endpoint |
| Eisai Co., Ltd. and Biogen Inc. announced today that an Independent Data Monitoring Committee has determined that BAN2401, an anti-amyloid beta protofibril antibody, did not meet the criteria for success based on a Bayesian analysis at 12 months as the primary endpoint in an 856-patient Phase II clinical study (Study 201). more info >> |
|
| Monday, December 18, 2017 |
|
|
Eisai Launches Educational Materials for Understanding Dementia |
| Eisai Co., Ltd. announced that it has created educational materials for understanding dementia and thinking about what one can do for elementary and secondary school students, and has commenced marketing these materials primarily to local governments, educational institutions as well as medical and nursing care professionals from today. more info >> |
|
| Wednesday, December 13, 2017 |
|
|
Eisai's Aricept Approved for Additional Indication of Severe Alzheimer's Disease in China |
| Eisai Co., Ltd. announced today that Aricept (donepezil hydrochloride) has been approved for the additional indication of severe Alzheimer's disease in China. Aricept is the first Alzheimer's disease treatment with a broad indication that covers mild to severe Alzheimer's disease in China. more info >> |
|
| Friday, December 8, 2017 |
|
|
Eisai: Updated Analysis of Phase Ib/II Study of Eribulin and Pembrolizumab Combination Regimen |
| Eisai Co., Ltd. announced today that a presentation on the updated analysis of a global Phase Ib/II clinical study of its in-house discovered and developed anticancer agent eribulin mesylate in combination with the anti-PD-1 therapy pembrolizumab developed by Merck & Co., Inc. more info >> |
|
| Wednesday, December 6, 2017 |
|
|
Eisai Submits Application for Expanded Indication Covering Hepatocellular Carcinoma for Anticancer Agent Lenvima in Taiwan |
| Eisai Co., Ltd. announced that it has submitted an application for its in-house discovered and developed anticancer agent lenvatinib mesylate (product names: Lenvima/Kisplyx, product name in Taiwan: "Lenvima") for an additional indication for use in the treatment of hepatocellular carcinoma (HCC) in Taiwan. more info >> |
|
| Thursday, November 30, 2017 |
|
|
Eisai's Resubmitted NDA for Anticancer Agent Halaven Accepted in China |
| Eisai Co., Ltd. announced today that the China Food and Drug Administration (CFDA) has accepted for review the resubmitted New Drug Application (NDA) for Eisai's anticancer agent eribulin mesylate (eribulin, product name: Halaven). more info >> |
|
| Friday, November 24, 2017 |
|
|
Eisai to Present Latest Data on Perampanel and Rufinamide at 71st American Epilepsy Society Annual Meeting |
| Eisai Co., Ltd. announced today that the latest data on its antiepileptic drugs (AED) perampanel and rufinamide will be presented at the 71st American Epilepsy Society (AES) Annual Meeting to be held from December 1 to 5, 2017 in Washington D.C. in the United States. more info >> |
|
| Monday, November 20, 2017 |
|
|
Eisai Receives IT Business Award for Medication Administration Support Device e-OKUSURI-SAN |
| Eisai Co., Ltd. has announced that it received an "IT Business Award" for its medication administration support device e-OKUSURI-SAN at the fiscal 2017 (35th) IT Awards held by the Japan Institute of Information Technology (JiIT). more info >> |
|
|
|
